Tatiana Novobrantseva

Tatiana Novobrantseva

Company: Verseau Therapeutics

Job title: Co-founder & Chief Scientific Officer

Bio:

Before co-founding Verseau, Tatiana consulted for multiple companies on immunological aspects of drug development across different stages and therapeutic modalities in a variety of autoimmune, cancer and rare disease indications. At her prior position as Director of Tumor Immunology at Jounce Therapeutics, Tatiana defined research plans for several programs at the company’s inception, as well as led a portfolio of programs on (re)activating the immune system against cancer. Previously, Tatiana served as Associate Director at Alnylam Pharmaceuticals and Scientist II at Biogen. Tatiana’s scientific accomplishments include identifying and validating novel therapeutic target and indications, discovering the critical role for B cells in liver fibrosis, developing novel mechanistic insights for multiple therapeutic programs, pushing the envelope on siRNA delivery and championing a dendritic cell cancer vaccine clinical program. Tatiana completed her Ph.D. in Immunology with Dr. Klaus Rajewsky at the University of Cologne in Germany, focusing on B cell development and function. She holds a diploma of engineer-physicist and an M.S. in molecular biology from Moscow Institute of Physics and Technology.

Seminars:

Completing the Immune Cycle by Targeting Novel Macrophage Checkpoints 12:45 pm

Download The Full Event Guide Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.